Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 8076304
Methods and compositions for the diagnosis and treatment of cyclin A-1 associated conditions
granted -
US 8076099
Biomarkers of Francisella infection
granted -
US 8075904
High aspect ratio template and method for producing same for central and peripheral nerve repair
granted -
US 8075881
Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
granted -
US 8071109
VMP-like sequences of pathogenic Borrelia
granted -
US 8071645
Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
granted -
US 8071535
Guanidinium derivatives for improved cellular transport
granted -
US 8071074
Preventing airway mucus production by administration of EGF-R antagonists
granted -
US 8071107
Nucleic acids encoding modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins
granted -
US 8071137
Method for treatment of cartilage disorders with centella extract
granted -
US 8067377
Peptide compositions for targeting adipose tissue
granted -
US 8067390
Therapeutic targeting of interleukins using siRNA in neutral liposomes
granted -
US 8067237
Scaffolds for cell transplantation
granted -
US 8067636
Dihydrazide compounds, preparation and uses thereof
granted -
US 8067460
5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel
granted -
US 8063089
Inhibitors of nucleophosmin (NPM) and methods for inducing apoptosis
granted -
US 8062647
High concentration baclofen preparations
granted -
US 8062643
Use of neurotoxin therapy for treatment of urologic and related disorders
granted -
US 8062654
Drug releasing biodegradable fiber for delivery of therapeutics
granted -
US 8058237
Stable composition of GDF-5 and method of storage
granted -
US 8058063
Method of producing region-specific neurons from human neuronal stem cells
granted -
US 8057807
Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction
granted -
US 8058295
Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
granted -
US 8053412
NELL-1 peptides
granted -
US 8053416
Isolation and structure of turbostatins 1-4
granted -
US 8052970
Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis
granted -
US 8053424
Composition and method of treating hearing loss
granted -
US 8048851
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
granted -
US 8048990
Modified vitamin K-dependent polypeptides
granted -
US 8048646
NELL peptide expression systems and bone formation activity of NELL peptide
granted -
US 8048844
Preventing airway mucus production by administration of EGF-R antagonists
granted -
US 8044033
Fluorocytidine derivatives and COX-2 inhibitors for the treatment of cancer
granted -
US 8044018
Reagents and methods for smooth muscle therapies
granted -
US 8044259
Determining the capability of a test compound to affect solid tumor stem cells
granted -
US 8044026
Composition for promoting cartilage formation or repair comprising a NELL gene product and method of treating cartilage-related conditions using such composition
granted -
US 8043853
Postnatal gut neural crest stem cells
granted -
US 8043820
Diagnostic methods for the detection of risk of autistic spectrum disorder
granted -
US 8039257
Pre-transplant accomodated organs resistant to anti-donor immunity
granted -
US 8039001
Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection
granted -
US 8039008
Identification of residues critical for the function of the vibrio cholerae virulence regulator ToxT by scanning alanine mutagenesis
granted -
US 8034768
Composition and method for the treatment of diseases affected by histone deacetylase inhibitors
granted -
US 8034556
Regulation of glucose and insulin levels by GnT-4 glycosyltransferase activity
granted -
US 8034821
Selective serine/threonine kinase inhibitors
granted -
US 8034329
Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells
granted -
US 8034363
Sustained release systems of ascorbic acid phosphate
granted -
US 8034384
Method of increasing biocompatibility of medical device by generating nitric oxide
granted -
US 8030074
In vivo incorporation of unnatural amino acids
granted -
US 8030012
Id-1 and Id-2 genes and products as markers of epithelial cancer
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory